Global Adrenocortical Carcinoma Market Report 2025

Adrenocortical Carcinoma Global Market Report 2025 – By Type (Localized Adrenocortical Carcinoma, Metastatic Adrenocortical Carcinoma), By Therapy (Surgery, Laparoscopic Surgery, Open Surgery, Chemotherapy, Targeted Therapy, Radiation Therapy, External Beam Radiation Therapy, Bratchytherapy, Adjuvant Therapy, Other Therapy), By End User (Hospitals And Clinics, Ambulatory Surgical Centers, Cancer Research Institutes) – Market Size, Trends, And Global Forecast 2025-2034

Adrenocortical Carcinoma Global Market Report 2025

Report Price : $4490.00 | Pages : | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Adrenocortical Carcinoma Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN

Adrenocortical Carcinoma Market Definition

Adrenocortical carcinoma (ACC) is a rare and aggressive cancer that originates in the outer layer (cortex) of the adrenal glands. The adrenal glands are small, triangular organs on top of each kidney that produce hormones essential for regulating metabolism, immune response, blood pressure, and stress response. Adrenocortical carcinoma (ACC) can cause hormone imbalances, leading to symptoms such as weight gain, high blood pressure, or virilization (excess male traits).

The main types of adrenocortical carcinoma are localized adrenocortical carcinoma and metastatic adrenocortical carcinoma. Localized adrenocortical carcinoma is a rare and aggressive cancer that originates in the adrenal glands and is confined to the adrenal gland without spreading to other parts of the body. These types are treated through various therapeutic approaches, including surgery, chemotherapy, targeted therapy, radiation therapy, and adjuvant therapy. The key end users of these treatments include hospitals and clinics, ambulatory surgical centers, and cancer research institutes.

Adrenocortical Carcinoma Market Segmentation

The adrenocortical carcinoma market covered in this report is segmented –

1) By Type: Localized Adrenocortical Carcinoma, Metastatic Adrenocortical Carcinoma

2) By Therapy: Surgery, Laparoscopic Surgery, Open Surgery, Chemotherapy, Targeted Therapy, Radiation Therapy, External Beam Radiation Therapy, Bratchytherapy, Adjuvant Therapy, Other Therapy

3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Cancer Research Institutes

Subsegments:

1) By Localized Adrenocortical Carcinoma: Early-Stage Localized Adrenocortical Carcinoma, Advanced Localized Adrenocortical Carcinoma

2) By Metastatic Adrenocortical Carcinoma: Metastasis To Distant Organs, Local Regional Metastasis

Adrenocortical Carcinoma Market Size and growth rate 2025 to 2029: Graph

Adrenocortical Carcinoma Market Size 2025 And Growth Rate

The adrenocortical carcinoma market size has grown steadily in recent years. It will grow from $3.60 billion in 2024 to $3.77 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to increasing incidence of adrenocortical carcinoma, growing awareness of rare endocrine tumors, increased government and research funding, growing patient support and advocacy groups, and rising prevalence of rare cancers.

Adrenocortical Carcinoma Market Growth Forecast

The adrenocortical carcinoma market size is expected to see steady growth in the next few years. It will grow to $4.47 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to increased use of combination therapies, rising adoption of personalized medicine approaches, expanding clinical trials, increased participation in international research networks, and increased government and research funding. Major trends in the forecast period include advancements in genomic sequencing and personalized medicine, targeted therapy innovations, immunotherapy developments, liquid biopsy technology, and advances in biomarker identification.

Adrenocortical Carcinoma Market Driver: The Increase In Prevalence Rates Of Rare Cancer Growth On The Market

The increase in prevalence rates of rare cancer is expected to propel the growth of the adrenocortical carcinoma market going forward. Rare cancers are referred to as distinguished by low incidence rates and a significant influence on patient outcomes, needing specialist techniques for diagnosis and therapy. The increase in prevalence rates of rare cancer is driven by several factors, such as developments in diagnostic methods that have enhanced the detection of adrenocortical carcinoma, enabling the early identification of instances that could have gone undetected in the past. Adrenocortical carcinoma (ACC) contributes to the increase in prevalence rates of rare cancers by being a relatively uncommon yet aggressive cancer type, highlighting the need for improved diagnosis and treatment strategies. For instance, in February 2022, according to a report by the International Agency for Research on Cancer of the World Health Organization, a Switzerland-based intergovernmental organization, nearly six new cases of rare cancers are diagnosed per 100,000 individuals in the US each year. Therefore, the increase in prevalence rates of rare cancer will drive the growth of the adrenocortical carcinoma market.

Global Adrenocortical Carcinoma Market Major Players

Major companies operating in the adrenocortical carcinoma market are Roche Holding AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Ferring Pharmaceuticals Inc., Exelixis Inc., Alnylam Pharmaceuticals Inc., Mylan N.V., HRA Pharma S.A., Servier Laboratories, Tempest Therapeutics Inc., Orphagen Pharmaceuticals Inc., Millendo Therapeutics Inc.

Global Adrenocortical Carcinoma Market Trend: Innovative Therapeutic Approaches In Treatment

Major companies operating in the adrenocortical carcinoma market are focusing on developing innovative therapies, such as small-molecule drugs, to target specific tumor pathways and improve patient outcomes. A small-molecule drug is a low molecular weight compound that penetrates cells to target proteins or enzymes, regulating biological processes and treating diseases such as adrenocortical carcinoma by inhibiting tumor growth pathways. For instance, in January 2023, Orphagen Pharmaceuticals, Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted Rare Pediatric Disease Designation (RPDD) for its investigational drug OR-449, aimed at treating pediatric adrenocortical carcinoma (ACC). This drug aims to treat pediatric ACC, a rare and aggressive cancer primarily affecting children. The disease often presents with symptoms linked to hormonal overproduction, such as virilization and Cushing syndrome. Diagnosis involves imaging and hormonal assessments, with prognosis influenced by factors such as age at diagnosis and tumor resectability.

Adrenocortical Carcinoma Market Merger And Acquisition: Esteve Pharmaceuticals Expands Rare Disease Portfolio With Acquisition Of HRA Pharma

In October 2024, Esteve Pharmaceuticals, S.A., a Spain-based pharmaceutical company, acquired HRA Pharma Rare Diseases from Perrigo Company plc for an undisclosed amount. With this acquisition, Esteve Pharmaceuticals aims to expand its portfolio of treatments for rare diseases, accelerate international growth, enhance patient care, and increase market reach. HRA Pharma Rare Diseases is a France-based pharmaceutical company specializing in treating rare diseases, including adrenocortical carcinoma.

Regional Outlook For The Global Adrenocortical Carcinoma Market

North America was the largest region in the adrenocortical carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adrenocortical carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the adrenocortical carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Adrenocortical Carcinoma Market?

The adrenocortical carcinoma market consists of revenues earned by entities by providing services such as diagnostic services, medical treatments, patient management services, clinical trials, and research. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Adrenocortical Carcinoma Industry?

The adrenocortical carcinoma market research report is one of a series of new reports from The Business Research Company that provides adrenocortical carcinoma market statistics, including the adrenocortical carcinoma industry global market size, regional shares, competitors with the adrenocortical carcinoma market share, detailed adrenocortical carcinoma market segments, market trends, and opportunities, and any further data you may need to thrive in the adrenocortical carcinoma industry. This adrenocortical carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Adrenocortical Carcinoma Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 3.77 billion
Revenue Forecast In 2034 $4.47 billion
Growth Rate CAGR of 4.4% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The adrenocortical carcinoma market covered in this report is segmented –
1) By Type: Localized Adrenocortical Carcinoma, Metastatic Adrenocortical Carcinoma
2) By Therapy: Surgery, Laparoscopic Surgery, Open Surgery, Chemotherapy, Targeted Therapy, Radiation Therapy, External Beam Radiation Therapy, Bratchytherapy, Adjuvant Therapy, Other Therapy
3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Cancer Research Institutes Subsegments:
1) By Localized Adrenocortical Carcinoma: Early-Stage Localized Adrenocortical Carcinoma, Advanced Localized Adrenocortical Carcinoma
2) By Metastatic Adrenocortical Carcinoma: Metastasis To Distant Organs, Local Regional Metastasis
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Roche Holding AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Ferring Pharmaceuticals Inc., Exelixis Inc., Alnylam Pharmaceuticals Inc., Mylan N.V., HRA Pharma S.A., Servier Laboratories, Tempest Therapeutics Inc., Orphagen Pharmaceuticals Inc., Millendo Therapeutics Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Adrenocortical Carcinoma Market Characteristics

    3. Adrenocortical Carcinoma Market Trends And Strategies

    4. Adrenocortical Carcinoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

    5. Global Adrenocortical Carcinoma Growth Analysis And Strategic Analysis Framework

    5.1. Global Adrenocortical Carcinoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Adrenocortical Carcinoma Market Growth Rate Analysis

    5.4. Global Adrenocortical Carcinoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Adrenocortical Carcinoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Adrenocortical Carcinoma Total Addressable Market (TAM)

    6. Adrenocortical Carcinoma Market Segmentation

    6.1. Global Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Localized Adrenocortical Carcinoma

    Metastatic Adrenocortical Carcinoma

    6.2. Global Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Surgery

    Laparoscopic Surgery

    Open Surgery

    Chemotherapy

    Targeted Therapy

    Radiation Therapy

    External Beam Radiation Therapy

    Brachytherapy

    Adjuvant Therapy

    Other Therapy

    6.3. Global Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospitals And Clinics

    Ambulatory Surgical Centers

    Cancer Research Institutes

    6.4. Global Adrenocortical Carcinoma Market, Sub-Segmentation Of Localized Adrenocortical Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Early-Stage Localized Adrenocortical Carcinoma

    Advanced Localized Adrenocortical Carcinoma

    6.5. Global Adrenocortical Carcinoma Market, Sub-Segmentation Of Metastatic Adrenocortical Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Metastasis To Distant Organs

    Local Regional Metastasis

    7. Adrenocortical Carcinoma Market Regional And Country Analysis

    7.1. Global Adrenocortical Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Adrenocortical Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Adrenocortical Carcinoma Market

    8.1. Asia-Pacific Adrenocortical Carcinoma Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Adrenocortical Carcinoma Market

    9.1. China Adrenocortical Carcinoma Market Overview

    9.2. China Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Adrenocortical Carcinoma Market

    10.1. India Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Adrenocortical Carcinoma Market

    11.1. Japan Adrenocortical Carcinoma Market Overview

    11.2. Japan Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Adrenocortical Carcinoma Market

    12.1. Australia Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Adrenocortical Carcinoma Market

    13.1. Indonesia Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Adrenocortical Carcinoma Market

    14.1. South Korea Adrenocortical Carcinoma Market Overview

    14.2. South Korea Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Adrenocortical Carcinoma Market

    15.1. Western Europe Adrenocortical Carcinoma Market Overview

    15.2. Western Europe Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Adrenocortical Carcinoma Market

    16.1. UK Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Adrenocortical Carcinoma Market

    17.1. Germany Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Adrenocortical Carcinoma Market

    18.1. France Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Adrenocortical Carcinoma Market

    19.1. Italy Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Adrenocortical Carcinoma Market

    20.1. Spain Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Adrenocortical Carcinoma Market

    21.1. Eastern Europe Adrenocortical Carcinoma Market Overview

    21.2. Eastern Europe Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Adrenocortical Carcinoma Market

    22.1. Russia Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Adrenocortical Carcinoma Market

    23.1. North America Adrenocortical Carcinoma Market Overview

    23.2. North America Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Adrenocortical Carcinoma Market

    24.1. USA Adrenocortical Carcinoma Market Overview

    24.2. USA Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Adrenocortical Carcinoma Market

    25.1. Canada Adrenocortical Carcinoma Market Overview

    25.2. Canada Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Adrenocortical Carcinoma Market

    26.1. South America Adrenocortical Carcinoma Market Overview

    26.2. South America Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Adrenocortical Carcinoma Market

    27.1. Brazil Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Adrenocortical Carcinoma Market

    28.1. Middle East Adrenocortical Carcinoma Market Overview

    28.2. Middle East Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Adrenocortical Carcinoma Market

    29.1. Africa Adrenocortical Carcinoma Market Overview

    29.2. Africa Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Adrenocortical Carcinoma Market Competitive Landscape And Company Profiles

    30.1. Adrenocortical Carcinoma Market Competitive Landscape

    30.2. Adrenocortical Carcinoma Market Company Profiles

    30.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

    31. Adrenocortical Carcinoma Market Other Major And Innovative Companies

    31.1. Medtronic plc

    31.2. Eli Lilly and Company

    31.3. Teva Pharmaceutical Industries Ltd.

    31.4. Astellas Pharma Inc.

    31.5. Sun Pharmaceutical Industries Ltd.

    31.6. Ipsen S.A.

    31.7. Ferring Pharmaceuticals Inc.

    31.8. Exelixis Inc.

    31.9. Alnylam Pharmaceuticals Inc.

    31.10. Mylan N.V.

    31.11. HRA Pharma S.A.

    31.12. Servier Laboratories

    31.13. Tempest Therapeutics Inc.

    31.14. Orphagen Pharmaceuticals Inc.

    31.15. Millendo Therapeutics Inc.

    32. Global Adrenocortical Carcinoma Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Adrenocortical Carcinoma Market

    34. Recent Developments In The Adrenocortical Carcinoma Market

    35. Adrenocortical Carcinoma Market High Potential Countries, Segments and Strategies

    35.1 Adrenocortical Carcinoma Market In 2029 - Countries Offering Most New Opportunities

    35.2 Adrenocortical Carcinoma Market In 2029 - Segments Offering Most New Opportunities

    35.3 Adrenocortical Carcinoma Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Adrenocortical Carcinoma Market, Sub-Segmentation Of Localized Adrenocortical Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Adrenocortical Carcinoma Market, Sub-Segmentation Of Metastatic Adrenocortical Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Adrenocortical Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Adrenocortical Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Asia-Pacific, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Asia-Pacific, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: China, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: China, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: India, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: India, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: Japan, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: Japan, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Australia, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Australia, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Indonesia, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Indonesia, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: South Korea, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: South Korea, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Western Europe, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Western Europe, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: UK, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: UK, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Germany, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Germany, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: France, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: France, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Italy, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Italy, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Spain, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Spain, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Eastern Europe, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Eastern Europe, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Russia, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Russia, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: North America, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: North America, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: USA, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: USA, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: Canada, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: Canada, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: South America, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: South America, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Brazil, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Brazil, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Middle East, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Middle East, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Africa, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Africa, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Roche Holding AG Financial Performance
  • Table 77: Merck & Co. Inc. Financial Performance
  • Table 78: Sanofi S.A. Financial Performance
  • Table 79: Bristol-Myers Squibb Company Financial Performance
  • Table 80: AstraZeneca PLC Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Adrenocortical Carcinoma Market, Sub-Segmentation Of Localized Adrenocortical Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Adrenocortical Carcinoma Market, Sub-Segmentation Of Metastatic Adrenocortical Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Adrenocortical Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Adrenocortical Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Asia-Pacific, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Asia-Pacific, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: China, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: China, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: India, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: India, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: Japan, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: Japan, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Australia, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Australia, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Indonesia, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Indonesia, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: South Korea, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: South Korea, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Western Europe, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Western Europe, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: UK, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: UK, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Germany, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Germany, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: France, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: France, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Italy, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Italy, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Spain, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Spain, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Eastern Europe, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Eastern Europe, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Russia, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Russia, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: North America, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: North America, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: USA, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: USA, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: Canada, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: Canada, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: South America, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: South America, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Brazil, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Brazil, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Middle East, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Middle East, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Africa, Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Africa, Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Roche Holding AG Financial Performance
  • Figure 77: Merck & Co. Inc. Financial Performance
  • Figure 78: Sanofi S.A. Financial Performance
  • Figure 79: Bristol-Myers Squibb Company Financial Performance
  • Figure 80: AstraZeneca PLC Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the Adrenocortical Carcinoma market?

Adrenocortical carcinoma (ACC) is a rare and aggressive cancer that originates in the outer layer (cortex) of the adrenal glands. The adrenal glands are small, triangular organs on top of each kidney that produce hormones essential for regulating metabolism, immune response, blood pressure, and stress response. Adrenocortical carcinoma (ACC) can cause hormone imbalances, leading to symptoms such as weight gain, high blood pressure, or virilization (excess male traits). For further insights on the Adrenocortical Carcinoma market, request a sample here

How will the Adrenocortical Carcinoma market drivers and restraints affect the market dynamics? What forces will shape the Adrenocortical Carcinoma industry going forward?

The Adrenocortical Carcinoma market major growth driver - The Increase In Prevalence Rates Of Rare Cancer Growth On The Market. For further insights on the Adrenocortical Carcinoma market, request a sample here

What is the forecast market size or the forecast market value of the Adrenocortical Carcinoma market?

The Adrenocortical Carcinoma market size has grown strongly in recent years. The adrenocortical carcinoma market size has grown steadily in recent years. It will grow from $3.60 billion in 2024 to $3.77 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to increasing incidence of adrenocortical carcinoma, growing awareness of rare endocrine tumors, increased government and research funding, growing patient support and advocacy groups, and rising prevalence of rare cancers. The adrenocortical carcinoma market size is expected to see steady growth in the next few years. It will grow to $4.47 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to increased use of combination therapies, rising adoption of personalized medicine approaches, expanding clinical trials, increased participation in international research networks, and increased government and research funding. Major trends in the forecast period include advancements in genomic sequencing and personalized medicine, targeted therapy innovations, immunotherapy developments, liquid biopsy technology, and advances in biomarker identification. For further insights on the Adrenocortical Carcinoma market, request a sample here

How is the Adrenocortical Carcinoma market segmented?

The adrenocortical carcinoma market covered in this report is segmented –
1) By Type: Localized Adrenocortical Carcinoma, Metastatic Adrenocortical Carcinoma
2) By Therapy: Surgery, Laparoscopic Surgery, Open Surgery, Chemotherapy, Targeted Therapy, Radiation Therapy, External Beam Radiation Therapy, Bratchytherapy, Adjuvant Therapy, Other Therapy
3) By End User: Hospitals And Clinics, Ambulatory Surgical Centers, Cancer Research Institutes Subsegments:
1) By Localized Adrenocortical Carcinoma: Early-Stage Localized Adrenocortical Carcinoma, Advanced Localized Adrenocortical Carcinoma
2) By Metastatic Adrenocortical Carcinoma: Metastasis To Distant Organs, Local Regional Metastasis For further insights on the Adrenocortical Carcinoma market,
request a sample here

Which region has the largest share of the Adrenocortical Carcinoma market? What are the other regions covered in the report?

North America was the largest region in the adrenocortical carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adrenocortical carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Adrenocortical Carcinoma market, request a sample here.

Who are the major players in the Adrenocortical Carcinoma market?

Major companies operating in the adrenocortical carcinoma market are Roche Holding AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Ferring Pharmaceuticals Inc., Exelixis Inc., Alnylam Pharmaceuticals Inc., Mylan N.V., HRA Pharma S.A., Servier Laboratories, Tempest Therapeutics Inc., Orphagen Pharmaceuticals Inc., Millendo Therapeutics Inc. . For further insights on the Adrenocortical Carcinoma market, request a sample here.

What are the key trends in the Adrenocortical Carcinoma market?

Major trends in the Adrenocortical Carcinoma market include Innovative Therapeutic Approaches In Treatment. For further insights on the Adrenocortical Carcinoma market, request a sample here.

What are the major opportunities in the Adrenocortical Carcinoma market? What are the strategies for the Adrenocortical Carcinoma market?

For detailed insights on the major opportunities and strategies in the Adrenocortical Carcinoma market, request a sample here.

How does the Adrenocortical Carcinoma market relate to the overall economy and other similar markets?

For detailed insights on Adrenocortical Carcinoma's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Adrenocortical Carcinoma industry?

For detailed insights on the mergers and acquisitions in the Adrenocortical Carcinoma industry, request a sample here.

What are the key dynamics influencing the Adrenocortical Carcinoma market growth? SWOT analysis of the Adrenocortical Carcinoma market.

For detailed insights on the key dynamics influencing the Adrenocortical Carcinoma market growth and SWOT analysis of the Adrenocortical Carcinoma industry, request a sample here.